Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Phase I study of the heparanase inhibitor Roneparstat: an innovative approach for multiple myeloma therapy.

Galli M, Chatterjee M, Grasso M, Specchia G, Magen H, Einsele H, Celeghini I, Barbieri P, Paoletti D, Pace S, Sanderson RD, Rambaldi A, Nagler A.

Haematologica. 2018 Apr 26. pii: haematol.2017.182865. doi: 10.3324/haematol.2017.182865. [Epub ahead of print] No abstract available.

2.

Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma.

Higgs JT, Lee JH, Wang H, Ramani VC, Chanda D, Hardy CY, Sanderson RD, Ponnazhagan S.

Blood Adv. 2017 Nov 21;1(25):2375-2385. doi: 10.1182/bloodadvances.2017007310. eCollection 2017 Nov 28.

3.

Opposing Functions of Heparanase-1 and Heparanase-2 in Cancer Progression.

Vlodavsky I, Gross-Cohen M, Weissmann M, Ilan N, Sanderson RD.

Trends Biochem Sci. 2018 Jan;43(1):18-31. doi: 10.1016/j.tibs.2017.10.007. Epub 2017 Nov 20. Review.

PMID:
29162390
4.

Proteases and glycosidases on the surface of exosomes: Newly discovered mechanisms for extracellular remodeling.

Sanderson RD, Bandari SK, Vlodavsky I.

Matrix Biol. 2017 Oct 26. pii: S0945-053X(17)30311-6. doi: 10.1016/j.matbio.2017.10.007. [Epub ahead of print] Review.

PMID:
29106944
5.

Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior.

Bandari SK, Purushothaman A, Ramani VC, Brinkley GJ, Chandrashekar DS, Varambally S, Mobley JA, Zhang Y, Brown EE, Vlodavsky I, Sanderson RD.

Matrix Biol. 2018 Jan;65:104-118. doi: 10.1016/j.matbio.2017.09.001. Epub 2017 Sep 6.

6.

NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma.

Hao M, Franqui-Machin R, Xu H, Shaughnessy J Jr, Barlogie B, Roodman D, Quelle DE, Janz S, Tomasson MH, Sanderson RD, Qiu L, Frech I, Tricot G, Zhan F.

Leukemia. 2017 Jul;31(7):1648-1650. doi: 10.1038/leu.2017.115. Epub 2017 Apr 12. No abstract available.

7.

Heparanase: From basic research to therapeutic applications in cancer and inflammation.

Vlodavsky I, Singh P, Boyango I, Gutter-Kapon L, Elkin M, Sanderson RD, Ilan N.

Drug Resist Updat. 2016 Nov;29:54-75. doi: 10.1016/j.drup.2016.10.001. Epub 2016 Oct 6. Review.

8.

Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy.

Sanderson RD, Elkin M, Rapraeger AC, Ilan N, Vlodavsky I.

FEBS J. 2017 Jan;284(1):42-55. doi: 10.1111/febs.13932. Epub 2016 Nov 16. Review.

9.

Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype.

Ramani VC, Vlodavsky I, Ng M, Zhang Y, Barbieri P, Noseda A, Sanderson RD.

Matrix Biol. 2016 Sep;55:22-34. doi: 10.1016/j.matbio.2016.03.006. Epub 2016 Mar 22.

10.

Recent Insights into Cell Surface Heparan Sulphate Proteoglycans and Cancer.

Couchman JR, Multhaupt H, Sanderson RD.

F1000Res. 2016 Jun 29;5. pii: F1000 Faculty Rev-1541. doi: 10.12688/f1000research.8543.1. eCollection 2016. Review.

11.

Syndecan-1 (CD138) Suppresses Apoptosis in Multiple Myeloma by Activating IGF1 Receptor: Prevention by SynstatinIGF1R Inhibits Tumor Growth.

Beauvais DM, Jung O, Yang Y, Sanderson RD, Rapraeger AC.

Cancer Res. 2016 Sep 1;76(17):4981-93. doi: 10.1158/0008-5472.CAN-16-0232. Epub 2016 Jun 30.

12.

Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins.

Jung O, Trapp-Stamborski V, Purushothaman A, Jin H, Wang H, Sanderson RD, Rapraeger AC.

Oncogenesis. 2016 Feb 29;5:e202. doi: 10.1038/oncsis.2016.5.

13.

Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma.

Ramani VC, Zhan F, He J, Barbieri P, Noseda A, Tricot G, Sanderson RD.

Oncotarget. 2016 Jan 12;7(2):1598-607. doi: 10.18632/oncotarget.6408.

14.

Fibronectin on the Surface of Myeloma Cell-derived Exosomes Mediates Exosome-Cell Interactions.

Purushothaman A, Bandari SK, Liu J, Mobley JA, Brown EE, Sanderson RD.

J Biol Chem. 2016 Jan 22;291(4):1652-63. doi: 10.1074/jbc.M115.686295. Epub 2015 Nov 24.

15.

Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features.

VanValkenburg ME, Pruitt GI, Brill IK, Costa L, Ehtsham M, Justement IT, Innis-Shelton RD, Salzman D, Reddy ES, Godby KN, Mikhail FM, Carroll AJ, Reddy VB, Sanderson RD, Justement LB, Sanders PW, Brown EE.

Cancer Causes Control. 2016 Jan;27(1):81-91. doi: 10.1007/s10552-015-0685-2. Epub 2015 Nov 23.

16.

Heparanase is a host enzyme required for herpes simplex virus-1 release from cells.

Hadigal SR, Agelidis AM, Karasneh GA, Antoine TE, Yakoub AM, Ramani VC, Djalilian AR, Sanderson RD, Shukla D.

Nat Commun. 2015 Apr 27;6:6985. doi: 10.1038/ncomms7985.

17.

Insights into the key roles of proteoglycans in breast cancer biology and translational medicine.

Theocharis AD, Skandalis SS, Neill T, Multhaupt HA, Hubo M, Frey H, Gopal S, Gomes A, Afratis N, Lim HC, Couchman JR, Filmus J, Sanderson RD, Schaefer L, Iozzo RV, Karamanos NK.

Biochim Biophys Acta. 2015 Apr;1855(2):276-300. doi: 10.1016/j.bbcan.2015.03.006. Epub 2015 Mar 28. Review.

18.

Shed syndecan-1 translocates to the nucleus of cells delivering growth factors and inhibiting histone acetylation: a novel mechanism of tumor-host cross-talk.

Stewart MD, Ramani VC, Sanderson RD.

J Biol Chem. 2015 Jan 9;290(2):941-9. doi: 10.1074/jbc.M114.608455. Epub 2014 Nov 17.

19.

Heparan sulfate in the nucleus and its control of cellular functions.

Stewart MD, Sanderson RD.

Matrix Biol. 2014 Apr;35:56-9. doi: 10.1016/j.matbio.2013.10.009. Epub 2013 Dec 3. Review.

20.

Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse.

Ramani VC, Sanderson RD.

Matrix Biol. 2014 Apr;35:215-22. doi: 10.1016/j.matbio.2013.10.005. Epub 2013 Oct 18.

21.

Heparanase inhibits osteoblastogenesis and shifts bone marrow progenitor cell fate in myeloma bone disease.

Ruan J, Trotter TN, Nan L, Luo R, Javed A, Sanderson RD, Suva LJ, Yang Y.

Bone. 2013 Nov;57(1):10-7. doi: 10.1016/j.bone.2013.07.024. Epub 2013 Jul 27.

22.

Involvement of heparanase in atherosclerosis and other vessel wall pathologies.

Vlodavsky I, Blich M, Li JP, Sanderson RD, Ilan N.

Matrix Biol. 2013 Jun 24;32(5):241-51. doi: 10.1016/j.matbio.2013.03.002. Epub 2013 Mar 13. Review.

23.

Heparanase: multiple functions in inflammation, diabetes and atherosclerosis.

Vlodavsky I, Iozzo RV, Sanderson RD.

Matrix Biol. 2013 Jun 24;32(5):220-2. doi: 10.1016/j.matbio.2013.03.001. Epub 2013 Mar 7. Review. No abstract available.

24.

Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes.

Thompson CA, Purushothaman A, Ramani VC, Vlodavsky I, Sanderson RD.

J Biol Chem. 2013 Apr 5;288(14):10093-9. doi: 10.1074/jbc.C112.444562. Epub 2013 Feb 21.

25.

The heparanase/syndecan-1 axis in cancer: mechanisms and therapies.

Ramani VC, Purushothaman A, Stewart MD, Thompson CA, Vlodavsky I, Au JL, Sanderson RD.

FEBS J. 2013 May;280(10):2294-306. doi: 10.1111/febs.12168. Epub 2013 Mar 4. Review.

26.

Heparanase enhances the insulin receptor signaling pathway to activate extracellular signal-regulated kinase in multiple myeloma.

Purushothaman A, Babitz SK, Sanderson RD.

J Biol Chem. 2012 Nov 30;287(49):41288-96. doi: 10.1074/jbc.M112.391417. Epub 2012 Oct 9.

27.

Targeting heparanase for cancer therapy at the tumor-matrix interface.

Sanderson RD, Iozzo RV.

Matrix Biol. 2012 Jun;31(5):283-4. doi: 10.1016/j.matbio.2012.05.001. No abstract available.

PMID:
22655968
28.

Heparan sulfate chains of syndecan-1 regulate ectodomain shedding.

Ramani VC, Pruett PS, Thompson CA, DeLucas LD, Sanderson RD.

J Biol Chem. 2012 Mar 23;287(13):9952-61. doi: 10.1074/jbc.M111.330803. Epub 2012 Feb 1.

29.

Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype.

Purushothaman A, Hurst DR, Pisano C, Mizumoto S, Sugahara K, Sanderson RD.

J Biol Chem. 2011 Sep 2;286(35):30377-83. doi: 10.1074/jbc.M111.254789. Epub 2011 Jul 11.

30.

SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.

Ritchie JP, Ramani VC, Ren Y, Naggi A, Torri G, Casu B, Penco S, Pisano C, Carminati P, Tortoreto M, Zunino F, Vlodavsky I, Sanderson RD, Yang Y.

Clin Cancer Res. 2011 Mar 15;17(6):1382-93. doi: 10.1158/1078-0432.CCR-10-2476. Epub 2011 Jan 21.

31.

Proteoglycans in cancer biology, tumour microenvironment and angiogenesis.

Iozzo RV, Sanderson RD.

J Cell Mol Med. 2011 May;15(5):1013-31. doi: 10.1111/j.1582-4934.2010.01236.x. Review.

32.

Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity.

Ramani VC, Yang Y, Ren Y, Nan L, Sanderson RD.

J Biol Chem. 2011 Feb 25;286(8):6490-9. doi: 10.1074/jbc.M110.183277. Epub 2010 Dec 3.

33.

Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL.

Yang Y, Ren Y, Ramani VC, Nan L, Suva LJ, Sanderson RD.

Cancer Res. 2010 Nov 1;70(21):8329-38. doi: 10.1158/0008-5472.CAN-10-2179. Epub 2010 Oct 26.

34.

Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis.

Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N, Vlodavsky I.

FEBS J. 2010 Oct;277(19):3890-903. doi: 10.1111/j.1742-4658.2010.07799.x. Epub 2010 Aug 31. Review.

35.

Tumor-derived syndecan-1 mediates distal cross-talk with bone that enhances osteoclastogenesis.

Kelly T, Suva LJ, Nicks KM, MacLeod V, Sanderson RD.

J Bone Miner Res. 2010 Jun;25(6):1295-304. doi: 10.1002/jbmr.16.

36.

Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis.

Purushothaman A, Uyama T, Kobayashi F, Yamada S, Sugahara K, Rapraeger AC, Sanderson RD.

Blood. 2010 Mar 25;115(12):2449-57. doi: 10.1182/blood-2009-07-234757. Epub 2010 Jan 22.

37.

Modification, crosslinking and reactive electrospinning of a thermoplastic medical polyurethane for vascular graft applications.

Theron JP, Knoetze JH, Sanderson RD, Hunter R, Mequanint K, Franz T, Zilla P, Bezuidenhout D.

Acta Biomater. 2010 Jul;6(7):2434-47. doi: 10.1016/j.actbio.2010.01.013. Epub 2010 Jan 18.

PMID:
20080215
38.

Myeloma bone disease.

Sanderson RD, Epstein J.

J Bone Miner Res. 2009 Nov;24(11):1783-8. doi: 10.1359/jbmr.090901. Review. No abstract available.

39.

Heparanase: busy at the cell surface.

Fux L, Ilan N, Sanderson RD, Vlodavsky I.

Trends Biochem Sci. 2009 Oct;34(10):511-9. doi: 10.1016/j.tibs.2009.06.005. Epub 2009 Sep 3. Review.

40.

Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo.

Khotskaya YB, Dai Y, Ritchie JP, MacLeod V, Yang Y, Zinn K, Sanderson RD.

J Biol Chem. 2009 Sep 18;284(38):26085-95. doi: 10.1074/jbc.M109.018473. Epub 2009 Jul 13.

41.

Heparanase regulates levels of syndecan-1 in the nucleus.

Chen L, Sanderson RD.

PLoS One. 2009;4(3):e4947. doi: 10.1371/journal.pone.0004947. Epub 2009 Mar 23.

42.

Non-anticoagulant heparins and inhibition of cancer.

Casu B, Vlodavsky I, Sanderson RD.

Pathophysiol Haemost Thromb. 2008;36(3-4):195-203. doi: 10.1159/000175157. Epub 2009 Jan 27. Review.

43.

Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma.

Purushothaman A, Chen L, Yang Y, Sanderson RD.

J Biol Chem. 2008 Nov 21;283(47):32628-36. doi: 10.1074/jbc.M806266200. Epub 2008 Sep 23.

44.

Non-enzymatic glycation of type I collagen diminishes collagen-proteoglycan binding and weakens cell adhesion.

Reigle KL, Di Lullo G, Turner KR, Last JA, Chervoneva I, Birk DE, Funderburgh JL, Elrod E, Germann MW, Surber C, Sanderson RD, San Antonio JD.

J Cell Biochem. 2008 Aug 1;104(5):1684-98. doi: 10.1002/jcb.21735.

45.

Syndecan-1: a dynamic regulator of the myeloma microenvironment.

Sanderson RD, Yang Y.

Clin Exp Metastasis. 2008;25(2):149-59. Epub 2007 Nov 20. Review.

46.

Adsorption of 2-acrylamido-2-methyl-1-propanesulfonic acid (AMPS) and related compounds onto montmorillonite clay.

Greesh N, Hartmann PC, Cloete V, Sanderson RD.

J Colloid Interface Sci. 2008 Mar 1;319(1):2-11. Epub 2007 Oct 18.

PMID:
17996883
47.

The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.

Yang Y, MacLeod V, Dai Y, Khotskaya-Sample Y, Shriver Z, Venkataraman G, Sasisekharan R, Naggi A, Torri G, Casu B, Vlodavsky I, Suva LJ, Epstein J, Yaccoby S, Shaughnessy JD Jr, Barlogie B, Sanderson RD.

Blood. 2007 Sep 15;110(6):2041-8. Epub 2007 May 29.

48.

Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis.

Yang Y, Macleod V, Miao HQ, Theus A, Zhan F, Shaughnessy JD Jr, Sawyer J, Li JP, Zcharia E, Vlodavsky I, Sanderson RD.

J Biol Chem. 2007 May 4;282(18):13326-33. Epub 2007 Mar 8.

49.

Expression of CD138 (Syndecan-1) in renal cell carcinoma is reduced with increasing nuclear grade.

Gökden N, Greene GF, Bayer-Garner IB, Spencer HJ, Sanderson RD, Gökden M.

Appl Immunohistochem Mol Morphol. 2006 Jun;14(2):173-7.

PMID:
16785785
50.

Synthesis and characterization of new cationic quaternary ammonium polymerizable surfactants.

Samakande A, Hartmann PC, Sanderson RD.

J Colloid Interface Sci. 2006 Apr 1;296(1):316-23. Epub 2005 Nov 2.

PMID:
16259996

Supplemental Content

Loading ...
Support Center